EPCAM and ovarian carcinoma: Patient‐derived HuP3D cultures identified that combination of trametinib and BIX02189 had a significant enhanced killing effect on EpCAM+ primary ovarian cancer cells in two out of the three patient‐derived HuP3D cultures, as well as confirmed the significant effect on survival of trametinib treatment for the same three ovarian cancer patients (#1–3) compared with untreated control (Figure 6G).